KLK3 and benign prostatic hyperplasia: The combination of these prostate biomarkers with PSA testing was better than PSA alone in identifying prostate cancer (AUC for panel of FLNA, FLNB, age, PSA, 0.64; PSA alone AUC, 0.58) and improved the prediction of high risk disease (AUC for panel of FLNB, age, and PSA, 0.81; PSA alone AUC, 0.71), low risk disease (AUC for panel of FLNB, age, PSA, and low Gleason Score, 0.72; PSA alone AUC, 0.63), and the prediction of cancer versus benign prostatic hyperplasia (AUC for panel of FLNA, KRT19, and age with PSA, 0.70; PSA alone AUC, 0.58).